![(A) Wildtype AF16 worms as compared with (B) *Cbr-dpy-10*, which shows the Dumpy phenotype.](25789430-2019-micropub.biology.000171){#f1}

Description
===========

Genomic editing of the roundworm *Caenorhabditis elegans* using the CRISPR/Cas9 system has allowed for widespread creation of null mutants -- vital for scientific understanding of this model organism. A closely-related nematode species, *Caenorhabditis briggsae*, is emerging as an alternative model organism to better understand how findings in *C. elegans* can broaden and develop the larger field of nematology (Gupta *et al.* 2007). To that end, we have developed an effective and efficient co-conversion CRISPR/Cas9 system for use in *C. briggsae* using the gene *dpy-10*.

We modified the universal STOP-IN cassette method, as described by Wang *et al.* (2018), for use in *C. briggsae* (Wang *et al.* 2018). Using the wildtype AF16 strain, we tested the method by choosing the gene *Cbr-dpy-10* because of its readily observed predicted phenotype. *Cbr-dpy-10* is a predicted one-to-one ortholog of *C. elegans* *dpy-10*, which encodes a protein important for cuticle development and has a phenotype characterized by short, fat animals relative to wild type (Brenner 1974).

A universal STOP-IN allele of *Cbr-dpy-10, sy1387,* was generated and confirmed by genotype sequencing. The expected phenotype was subsequently observed, consistent with the creation of a null allele ([Figure 1](#f1){ref-type="fig"}). Surprisingly, *sy1387* is dominant. Injections of 20 animals produced 15 successful injections; 247 animals from these 15 injections (F1) were singled out and allowed to self-fertilize to produce F2. 81% of the F1 Dumpy progeny were homozygous as evidenced by their segregation of only Dumpy progeny -- one of these candidates became *sy1387*. 2% of the F1s did not produce progeny. 17% of the 247 F1 Dumpy progeny were heterozygotes and had a mixture of Dumpy and non-Dumpy progeny; these non-Dumpy F2s only produced non-Dumpy progeny. This discovery of a dominant mutation will allow for more effective use of this as a co-conversion marker when screening for other mutations. We used *Cbr-dpy-10* as a potential co-CRISPR marker for a second target that will be described elsewhere. We used PCR to detect insertion of a STOP-IN cassette at this other locus; we screened 39 Dumpy strains to obtain 11 candidates for our target gene, from which we have three STOP-IN alleles.

Methods
=======

We used the universal STOP-IN cassette method essentially as described in Wang *et al.* (2018). Potential guide sequences were followed by a 5'-NGG-3' PAM site and were close to the start codon ATG of the target gene. The guide sequence for *Cbr-dpy-10* used in this protocol was ATTCGCGTCAGATGATGTAC, located at the beginning of the gene's second exon. To detect the stop-in insertion into *Cbr-dpy-10*, we used forward primer GAAAAACAACGGCAGAGACG and reverse primer TCCGCTTCCATAAGCACCAC.

In *sy1387*, the second exon of *Cbr-dpy-10* (shown below) was changed with the 41 basepair insert highlighted in red. This caused the early introduction of a stop codon (underlined) and a subsequent frameshift.

    CTATCGAACATTCTCGCTGACAACGAACTATTCGCGTCAGATGATGGAAGTTTGTCCAGAGCAGAGGTGACT
    AAGTGATAAGCTAGCTACCGGTGTGTCACAGGTCTTCAAATCGGATTTAGTTTGTTCTCATTCGTTATCGTT
    TGTGCCCTTCCTATTATGTACAATCATGTCCAGAACACAATTACTTATGTTGACAGAGAAATAGTGGCTTAT
    TGCGAA

Reagents
========

All CRISPR/Cas9 system reagents were ordered from IDT except for the Cas9 protein, which was kindly provided by Tsui-Fen Chou. Sequences were downloaded from WormBase.

Strain Generated:

PS8520 *Cbr-dpy-10* (*sy1387*) II
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